AbbVie registers Phase 1 PK study of trosunilimab given IV and SC in healthy adults
AbbVie's NCT07925983 trial will compare pharmacokinetics, immunogenicity and safety of intravenous and subcutaneous trosunilimab (ABBV-382) in healthy volunteers.
AbbVie had one new trial item listed for the week.
- A Phase 1 study of trosunilimab (also known as ABBV-382) is recruiting healthy adult volunteers to compare how the drug behaves in the body when given intravenously versus subcutaneously, including measures of pharmacokinetics, immunogenicity and safety following the two administration routes1. The trial, sponsored by AbbVie, plans to enroll 60 participants and is designed as a randomized, parallel-group study1, with a single U.S. site in Grayslake, Illinois, and an estimated primary completion date of May 2027.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.